Programme Thesis
The Women-Led Business Grant 2026 provides non-dilutive funding ($25K–$750K) to women entrepreneurs globally, aiming to close the gender gap in access to growth capital by supporting business expansion, innovation, and sustainability. The program exists to empower women-led ventures with financial resources, leadership coaching, and a global peer network, enabling them to scale without sacrificing equity.
Selection Criteria
Eligibility: business must be at least 51% women-owned OR have women in C-suite leadership positions. Evaluation criteria (inferred from program description): project scope and business needs, overall impact potential (economic, innovation, sustainability), clarity of funding use (working capital, pilot deployments, tech procurement, market research, ESG investments), business growth potential and sustainability, alignment with program goals (empowerment, leadership, innovation). No explicit scoring rubric provided; decisions based on application quality and fit within 4–6 weeks.
Past Winners / Cohort Profiles
No specific past winners or cohort profiles are listed on the page. The program is open globally across all sectors, suggesting a diverse range of women-led businesses from tech to social enterprises. Typical archetypes likely include early-stage ventures with clear growth plans, innovative products/services, and measurable impact.
Ideal Candidate Fingerprint
A woman-founded, pre-revenue or early-stage business with a scalable, innovative solution (e.g., AI, biotech, clean tech) that demonstrates strong growth potential and a clear use of funds for pilot deployments, technology procurement, or market expansion. The ideal applicant has a compelling narrative of female leadership, a well-defined project scope, and a plan to create economic or social impact.
Recommended Framing
Eniola should position the venture as a women-led AI/biotech breakthrough addressing critical unmet needs in drug resistance prediction, leveraging her unique pharmacist-turned-ML-engineer background. Emphasize the non-dilutive funding need for compute credits, ESM-2 fine-tuning on SKEMPI 3K mutations, and a Servier pilot—directly aligning with the grant's support for pilot deployments and technology procurement. Highlight the venture's innovation (100% mutation coverage, beating SOTA) and its potential for global health impact (oncology, antivirals, AMR) to resonate with the program's empowerment and innovation focus.
Watch Out
The venture is not yet incorporated, which may conflict with eligibility requiring a 'business' (likely a registered entity). The program's global scope and lack of sector specificity may dilute the venture's competitive edge if reviewers favor simpler, more traditional businesses. No named examples of past winners or clear sector preferences increase uncertainty.